Transplant rejection remains a serious and ongoing risk amongst kidney transplant recipients. The early findings of the 3C Study revealed that induction immunosuppression with alemtuzumab (a humanized monoclonal antibody capable of substantial lymphocyte depletion), combined with minimal exposure to standard immunosuppressive treatments, significantly reduced the risk of acute kidney transplant…
